Zai Lab (NASDAQ:ZLAB) Director William Lis Sells 7,040 Shares

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director William Lis sold 7,040 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $18.09, for a total transaction of $127,353.60. Following the sale, the director directly owned 50,437 shares in the company, valued at $912,405.33. This trade represents a 12.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Zai Lab Trading Down 0.6%

ZLAB stock opened at $18.37 on Thursday. The stock has a 50-day moving average price of $19.57 and a 200-day moving average price of $18.97. Zai Lab Limited Unsponsored ADR has a 1-year low of $15.96 and a 1-year high of $41.20. The firm has a market cap of $2.08 billion, a PE ratio of -11.34 and a beta of 0.78.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings data on Wednesday, April 1st. The company reported ($0.50) earnings per share (EPS) for the quarter. Zai Lab had a negative net margin of 39.29% and a negative return on equity of 24.32%. The business had revenue of $99.61 million during the quarter. On average, analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.23 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Zai Lab stock. SG Americas Securities LLC raised its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 41.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ZLAB. Cantor Fitzgerald cut their price target on Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Citigroup lowered their price objective on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Weiss Ratings downgraded shares of Zai Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 4th. JPMorgan Chase & Co. cut their target price on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. Finally, Wall Street Zen cut shares of Zai Lab from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Zai Lab currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.83.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.